世界卫生组织与国际疫苗研究所A组链球菌疫苗开发全球利益相关方磋商会议报告(2016年12月12-13日)
世界卫生组织(WHO)与国际疫苗研究所(IVI)于2016年12月12-13日在韩国首尔召开全球利益相关方磋商会议,讨论A组链球菌(GAS)疫苗开发的知识缺口、临床前模型与免疫学检测、疫苗研发管线现状及 licensure 与政策推荐路径。会议决定成立GAS疫苗工作组,协调制定全球疫苗价值主张、首选产品特性和技术研发路线图,并建立新的全球GAS疫苗联盟以推动战略规划。
要点
- GAS疫苗开发受科学、监管和商业壁垒阻碍,但全球疾病负担高,接种是紧迫的全球公共卫生目标。
- 会议决定成立GAS疫苗工作组,协调制定全球疫苗价值主张、首选产品特性和技术研发路线图。
- 将建立新的全球GAS疫苗联盟,驱动战略规划以预见 licensure、预认证和政策推荐的要求。
核心结论
- 会议确定成立GAS疫苗工作组协调制定全球疫苗价值主张、首选产品特性和技术研发路线图,并建立新的全球GAS疫苗联盟驱动战略规划以预见 licensure、预认证和政策推荐的要求。
研究设计与样本
- 世界卫生组织(WHO)与国际疫苗研究所(IVI)于2016年12月12-13日在韩国首尔召开全球利益相关方磋商会议。
主要发现
- 讨论主题包括:全球GAS流行病学、疾病负担和分子流行病学知识缺口;临床前模型对候选疫苗评价的贡献及新免疫学检测;GAS疫苗研发管线现状与未来;定义 licensure、政策推荐和疫苗可及性的路径。
临床怎么用
- 会议决定建立GAS疫苗工作组和新的全球GAS疫苗联盟以协调推进疫苗开发、licensure、预认证和政策推荐准备。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While progress towards a Group A Streptococcus (GAS) vaccine has been stalled by a combination of scientific, regulatory, and commercial barriers, the problem persists. The high and globally-distributed burden of disease attributable to GAS makes vaccination an imperative global public health goal. Advances across a range of scientific disciplines in understanding GAS diseases have made the goal a realistic one and focused attention on the need for coordinated global action. With a view to accelerating GAS vaccine development, the World Health Organization (WHO) and the International Vaccine Institute (IVI) convened a global stakeholder consultation on the 12th and 13th of December 2016, in Seoul, South Korea. Topics discussed included: (1) gaps in current knowledge of global GAS epidemiology, burden of disease, and molecular epidemiology; (2) contribution of pre-clinical models to candidate vaccine evaluation and new immunological assays to address GAS immunology knowledge gaps; (3) status and future of the GAS vaccine development pipeline; and (4) defining a pathway to licensure, policy recommendations and availability of a vaccine. The meeting determined to establish a GAS vaccine working group to coordinate preparation of a global vaccine values proposition, preferred product characteristics, and a technical research and development roadmap. A new global GAS vaccine consortium will drive strategic planning to anticipate requirements for licensure, prequalification, and policy recommendations.
引用
- Osowicki J, Vekemans J, Kaslow DC, et al. WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12-13 December 2016. Vaccine. 2018. PMID: 29496349. doi:10.1016/j.vaccine.2018.02.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。